🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Digestive System Neuroendocrine Tumor

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 18F-DOPA II - PET Imaging Optimization NCT04706910Phase 31 site📍 Edmonton University of Alberta · Tests: 18F-DOPA, Furosemide Injection A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) NCT04893785Phase 21 site📍 Naples National Cancer Institute, Naples · Tests: Cabozantinib and Temozolomide Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort NCT07808164n/a2 sites📍 Hanoi📍 Ho Chi Minh City Tam Anh Research Institute · Tests: IHC analysis for ENPP1, cGAS, and FAP expression DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Atezolizumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051n/a1 site📍 Austin Natera, Inc. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial NCT05773274Phase 242 sites📍 Birmingham📍 Phoenix📍 Tucson National Cancer Institute (NCI) · Tests: Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer NCT06636435Phase 15 sites📍 Kashiwa📍 Yokohama📍 Niigata Chiome Bioscience Inc. · Tests: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4, CBA-1205 Part 5 Nutrition Intervention for Pancreatic Cancer NCT07554560NA2 sites📍 Philadelphia📍 Philadelphia Children's Hospital of Philadelphia · Tests: Structured Lipid Medical Food Evaluation for NCI Surgery Branch Clinical Research Protocols NCT00001823n/a1 site📍 Bethesda National Cancer Institute (NCI) EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital NCT07302100n/a1 site📍 Strasbourg University Hospital, Strasbourg, France A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) NCT06505395Phase 21 site📍 Beijing CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Tests: SYHX2008 injection, Sandostatin LAR@ Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs NCT06356467n/a1 site📍 Milan IRCCS San Raffaele Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas NCT04268121Phase 214 sites📍 Amiens📍 Besançon📍 Clichy GERCOR - Multidisciplinary Oncology Cooperative Group · Tests: Neoadjuvant treatment, Adjuvant treatment Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not NCT07273409NA4 sites📍 Gothenburg📍 Lund📍 Stockholm Uppsala University · Tests: Debulking surgery A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites📍 Phoenix📍 San Francisco📍 Hartford BioNTech SE · Tests: BNT326, Pumitamig, Itraconazole, Paroxetine FTT PET/CT in Pancreatic Neuroendocrine Tumors NCT07114939Phase 11 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: [18F]FluorThanatrace GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site📍 Adelaide SAPU NANO (US) LLC · Tests: Sapu003, Exemestane 25 MG Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors NCT06663072Phase 11 site📍 Chicago University of Chicago · Tests: Fulvestrant, 177Lu-DOTATATE Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders NCT00830557n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: medical chart review, survey administration, biospecimen collection Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors NCT06908629NA1 site📍 Detroit Barbara Ann Karmanos Cancer Institute · Tests: Implementation of social determinants of health screening and referral
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy